Today before the opening
bell, it was announced that Galena Biopharma and Dr. Reddy’s Laboratories have
entered a strategic development and commercialization partnership on NeuVax(TM)
(nelipepimut-S) in India.
Dr. Reddy’s is an integrated
pharmaceutical company focused on providing affordable and innovative medicines
for healthier lives. By partnering with this global pharmaceutical company,
Gelena has expanded the depth of its pipeline by increasing the clinical
utility of NeuVax in another unmet medical need.
“This partnership with Dr.
Reddy’s is consistent with our strategy to expand the clinical utility of
NeuVax in unmet medical needs while simultaneously increasing the commercial
footprint of this innovative cancer immunotherapy,” said Mark J. Ahn, Ph.D., President
and CEO of Galena Biopharma. “Dr. Reddy’s is a leading pharmaceutical company
in India with significant commercialization and development expertise. The
gastric cancer trial will add a significant indication to our pipeline for
NeuVax, while doubling our potential patient population if approved.”
G V Prasad, Chairman and
CEO, Dr. Reddy’s commented, “The partnership accelerates our strong commitment
to innovation and efforts to bring newer options for cancer patients. We are
delighted with our partnership with Galena Biopharma and we believe NeuVax can
be a good potential treatment option to prevent the recurrence of breast and
gastric cancer.”
For more information, visit
www.galenabiopharma.com or www.drreddys.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
